{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:25:59Z","timestamp":1785281159154,"version":"3.55.0"},"reference-count":45,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AO"],"abstract":"<jats:p>Background: Metastatic renal cell carcinoma (mRCC) is notably resistant to chemotherapy and radiotherapy. However, tyrosine kinase inhibitors (TKIs) and checkpoint immunotherapy have significantly improved outcomes. Still, about 20% of patients experience disease progression as their best response to TKIs, and 16\u201363% endure severe toxicities, reducing quality of life. Optimizing dosing is therefore essential. Therapeutic drug monitoring (TDM) is a promising strategy for individualizing treatment. The TKI-TDM trial aims to identify a therapeutic plasma concentration range for six TKIs (axitinib, cabozantinib, pazopanib, sorafenib, sunitinib, tivozanib) in mRCC patients.\nMaterial and methods: This prospective observational study will enroll mRCC patients with at least 6 months of stable disease or regression on TKI therapy. Blood samples will be collected during routine care. Plasma concentrations of TKIs and metabolites will be measured using validated liquid chromatography-tandem mass spectrometry (LC-MS\/MS) methods. These levels will be correlated with clinical outcomes including objective response rate, progression-free survival, overall survival, and toxicity. Genetic analysis of UGT1A1 polymorphisms will explore their influence on pazopanib metabolism and response.\nInterpretation: Identifying plasma TKI levels associated with efficacy and reduced toxicity could minimize under- or overdosing, improving outcomes and quality of life. TDM may allow dose adjustments early in therapy, improving therapeutic management and reducing healthcare costs. Findings may also inform treatment of other cancers using TKIs or TKI-immunotherapy combinations. The trial (clinicaltrials.gov NCT04659343) is expected to conclude in 2028, with results in 2029.<\/jats:p>","DOI":"10.2340\/1651-226x.2025.43693","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:43:26Z","timestamp":1748911406000},"page":"729-733","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) for optimized outcome in patients with metastatic renal cell carcinoma. The TKI-TDM Trial. Study protocol"],"prefix":"10.2340","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-3206","authenticated-orcid":false,"given":"Jakob N.","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0543-6519","authenticated-orcid":false,"given":"Charlotte U.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8449-863X","authenticated-orcid":false,"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-0140","authenticated-orcid":false,"given":"Elke","family":"Hoffmann-L\u00fccke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0417-1195","authenticated-orcid":false,"given":"Eva","family":"Greibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4442-0535","authenticated-orcid":false,"given":"Niels","family":"Fristrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"113337","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","DOI":"10.3322\/caac.21763"},{"key":"113338","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3322\/caac.21763","DOI":"10.3322\/caac.21763"},{"key":"113339","doi-asserted-by":"crossref","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354\u201366.","DOI":"10.1056\/NEJMra1601333"},{"key":"113340","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMra1601333","DOI":"10.1056\/NEJMra1601333"},{"key":"113341","doi-asserted-by":"crossref","unstructured":"Soerensen AV, Donskov F, Hermann GG, Jensen NV, Petersen A, Spliid H, et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer. 2014;50(3):553\u201362.","DOI":"10.1016\/j.ejca.2013.10.010"},{"key":"113342","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390.","DOI":"10.1056\/NEJMoa1712126"},{"key":"113343","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1712126","DOI":"10.1056\/NEJMoa1712126"},{"key":"113344","doi-asserted-by":"crossref","unstructured":"Zivi A, Cerbone L, Recine F, Sternberg CN. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Expert Opin Drug Saf. 2012;11(5):851\u20139.","DOI":"10.1517\/14740338.2012.712108"},{"key":"113345","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1517\/14740338.2012.712108","DOI":"10.1517\/14740338.2012.712108"},{"key":"113346","doi-asserted-by":"crossref","unstructured":"Henriksen JN, B\u00f8ttger P, Hermansen CK, Ladefoged SA, Nissen PH, Hamilton-Dutoit S, et al. Pazopanib-induced liver toxicity in patients with metastatic renal cell carcinoma: effect of UGT1A1 polymorphism on pazopanib dose reduction, safety, and patient outcomes. Clin Genitourin Cancer. 2020;18(1):62\u20138.e2.","DOI":"10.1016\/j.clgc.2019.09.013"},{"key":"113347","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.013","DOI":"10.1016\/j.clgc.2019.09.013"},{"key":"113348","doi-asserted-by":"crossref","unstructured":"Mobaraki S, Nissen PH, Donskov F, Wozniak A, Van Herck Y, Coosemans L, et al. Cabozantinib induces isolated hyperbilirubinemia in renal cell carcinoma patients carrying the UGT1A1*28 polymorphism. Clin Genitourin Cancer. 2024;22(5):102180.","DOI":"10.1016\/j.clgc.2024.102180"},{"key":"113349","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102180","DOI":"10.1016\/j.clgc.2024.102180"},{"key":"113350","doi-asserted-by":"crossref","unstructured":"Eliasson E, Lindh JD, Malmstr\u00f6m RE, Beck O, Dahl M-L. Therapeutic drug monitoring for tomorrow. Eur J Clin Pharmacol. 2013;69(1):25\u201332.","DOI":"10.1007\/s00228-013-1504-x"},{"key":"113351","doi-asserted-by":"crossref","unstructured":"Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Lev\u00eaque D, et al. Review of therapeutic drug monitoring of anticancer drugs part two \u2013 targeted therapies. Eur J Cancer. 2014;50(12):2020\u201336.","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"113352","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2014.04.015","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"113353","doi-asserted-by":"crossref","unstructured":"Cardoso E, Guidi M, Blanchet B, Schneider MP, Decosterd LA, Buclin T, et al. Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: a critical review. Ther Drug Monit. 2019;44(1):33\u201344.","DOI":"10.1097\/FTD.0000000000000699"},{"key":"113354","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1097\/FTD.0000000000000699","DOI":"10.1097\/FTD.0000000000000699"},{"key":"113355","doi-asserted-by":"crossref","unstructured":"Powles T, Albiges L, Bex A, Gr\u00fcnwald V, Porta C, Procopio G, et al. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol. 2021;32(12):1511\u20139.","DOI":"10.1016\/j.annonc.2021.09.014"},{"key":"113356","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2021.09.014","DOI":"10.1016\/j.annonc.2021.09.014"},{"key":"113357","doi-asserted-by":"crossref","unstructured":"Rini BI, de La Motte Rouge T, Harzstark AL, Michaelson MD, Liu G, Gr\u00fcnwald V, et al. Five-year survival in patients with cytokine-\u00adrefractory metastatic renal cell carcinoma treated with axitinib. Clin Genitourin Cancer. 2013;11(2):107\u201314.","DOI":"10.1016\/j.clgc.2012.12.004"},{"key":"113358","unstructured":"https:\/\/doi.org\/10.1016\/"},{"key":"113359","doi-asserted-by":"crossref","unstructured":"j.clgc.2012.12.004","DOI":"10.1088\/1475-7516\/2012\/12\/004"},{"key":"113360","doi-asserted-by":"crossref","unstructured":"Mai H, Huang J, Zhang Y, Qu N, Qu H, Mei G-H, et al. In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study. Oncotarget. 2017;8(26):43458\u201369.","DOI":"10.18632\/oncotarget.16465"},{"key":"113361","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.18632\/oncotarget.16465","DOI":"10.18632\/oncotarget.16465"},{"key":"113362","doi-asserted-by":"crossref","unstructured":"Lankheet NAG, Kloth JSL, Gadellaa-Van Hooijdonk CGM, Cirkel GA, Mathijssen RHJ, Lolkema MPJK, et al. Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer. 2014;110(10):2441\u20139.","DOI":"10.1038\/bjc.2014.194"},{"key":"113363","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/bjc.2014.194","DOI":"10.1038\/bjc.2014.194"},{"key":"113364","doi-asserted-by":"crossref","unstructured":"Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, et al. Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma. Clin Cancer Research. 2018;24(13):3005\u201313.","DOI":"10.1158\/1078-0432.CCR-17-2652"},{"key":"113365","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2652","DOI":"10.1158\/1078-0432.CCR-17-2652"},{"key":"113366","doi-asserted-by":"crossref","unstructured":"Paludetto M-N, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, et al. Simultaneous monitoring of pazopanib and its metabolites by UPLC\u2013MS\/MS. J Pharm Biomed Anal. 2018;154:373\u201383.","DOI":"10.1016\/j.jpba.2018.03.013"},{"key":"113367","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jpba.2018.03.013","DOI":"10.1016\/j.jpba.2018.03.013"},{"key":"113368","unstructured":"Agency EM. Fotivda: EPAR \u2013 product information 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fotivda"},{"key":"113369","unstructured":"Agency EM. Votrient: EPAR \u2013 product information 2018. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/votrient"},{"key":"113370","unstructured":"Agency EM. Sutent: EPAR \u2013 product information 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sutent"},{"key":"113371","unstructured":"Agency EM. Inlyta: EPAR \u2013 product information 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inlyta"},{"key":"113372","unstructured":"Agency EM. Cometriq: EPAR \u2013 product information 2019. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cometriq"},{"key":"113373","unstructured":"Agency EM. Nexavar: EPAR \u2013 product information 2018. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexavar"},{"key":"113374","doi-asserted-by":"crossref","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"113375","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"113376","doi-asserted-by":"crossref","unstructured":"Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, et al. Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol. 2006;4(4):191\u20139.","DOI":"10.1037\/t25626-000"},{"key":"113377","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1037\/t25626-000","DOI":"10.1037\/t25626-000"},{"key":"113378","doi-asserted-by":"crossref","unstructured":"Henriksen JN, Andersen CU, Fristrup N. Therapeutic drug monitoring for tyrosine kinase inhibitors in metastatic renal cell carcinoma. Clin Genitourin Cancer. 2024;22(3):102064.","DOI":"10.1016\/j.clgc.2024.102064"},{"key":"113379","unstructured":"https:\/\/doi.org\/10.1016\/\u00adj.clgc.2024.102064"},{"key":"113380","doi-asserted-by":"crossref","unstructured":"Powles T, Albiges L, Bex A, Comperat E, Gr\u00fcnwald V, Kanesvaran R, et al. Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(8):692\u2013706.","DOI":"10.1016\/j.annonc.2024.05.537"},{"key":"113381","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.annonc.2024.05.537","DOI":"10.1016\/j.annonc.2024.05.537"}],"container-title":["Acta Oncologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43693\/50315","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/download\/43693\/50315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T18:04:33Z","timestamp":1756404273000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actaoncologica\/article\/view\/43693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":45,"URL":"https:\/\/doi.org\/10.2340\/1651-226x.2025.43693","relation":{},"ISSN":["1651-226X"],"issn-type":[{"value":"1651-226X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}